37854-59-4
中文名稱
7,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE
英文名稱
RO 08-2750
CAS
37854-59-4
分子式
C13H10N4O3
分子量
270.24
MOL 文件
37854-59-4.mol
更新日期
2024/11/05 14:06:54
37854-59-4 結(jié)構(gòu)式
基本信息
中文別名
化合物 T16766化合物RO 08-2750
英文別名
RO 08-27507,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE
2,3,4,10-Tetrahydro-7,10-dimethyl-2,4-dioxobenzo[g]pteridine-8-carboxaldehyde
Benzo[g]pteridine-8-carboxaldehyde, 2,3,4,10-tetrahydro-7,10-dimethyl-2,4-dioxo-
7,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-108466 | 7,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE Ro 08-2750 | 37854-59-4 | 1mg | 288元 |
| 2024/11/08 | HY-108466 | 7,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE Ro 08-2750 | 37854-59-4 | 5mg | 720元 |
| 2024/11/08 | HY-108466 | 7,10-DIMETHYL-2,4-DIOXOBENZO[G]PTERIDINE-8-CARBALDEHYDE Ro 08-2750 | 37854-59-4 | 10mM * 1mLin DMSO | 792元 |
常見(jiàn)問(wèn)題列表
生物活性
Ro 08-2750 是一種非肽、可逆的 NGF 抑制劑，能直接結(jié)合 NGF，IC50 值為 ~ 1 μM。Ro 08-2750 能抑制 NGF 結(jié)合 p75NTR 的優(yōu)于 TRKA。Ro 08-2750 是選擇性的 MSI RNA 結(jié)合抑制劑，其作用的 IC50 值為 2.7 μM。靶點(diǎn)
IC50: ~1 μM (NGF), 2.7 μM (MSI RNA-binding)
體外研究
Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75
NTR
anymore.
Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death.
Ro 08-2750 (5-10 μM; 8?hours) increases differentiation and apoptosis in myeloid leukemia cells.
Ro 08-2750 inhibits survival of human AML lines and patient cells.
Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature.
Apoptosis Analysis
| Cell Line: | MLL-AF9?+?BM cells |
| Concentration: | 5?μM, 10?μM |
| Incubation Time: | 8?hours |
| Result: | Increased apoptosis. |
體內(nèi)研究
Ro 08-2750 (13.75?mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo.
| Animal Model: | C57BL/6 wild type mice (10-12-weeks-old), MLL-AF9 murine leukemia model |
| Dosage: | 13.75?mg/kg |
| Administration: | Intraperitoneal injection, at days 1, 4, 7, 10, and 13 (one day on, two days off drug) |
| Result: | Inhibited c-MYC levels and reduced disease burden. |